UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

Annals of oncology, 2011-03, Vol.22 (3), p.515-523

2011

Volltextzugriff (PDF)

Does CDKN2A loss predict palbociclib benefit?

Current oncology (Toronto), 2015-12, Vol.22 (6), p.e498-501

2015

Volltextzugriff (PDF)

HER2-Neu in Breast Cancer: History and Future Directions

Annals of oncology, 2012-10, Vol.23, p.xi10-xi11

Swain, S.M.

2012

Volltextzugriff (PDF)

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Annals of oncology, 2018-03, Vol.29 (3), p.646-653

2018

Volltextzugriff (PDF)

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

Annals of oncology, 2014-06, Vol.25 (6), p.1116-1121

2014

Volltextzugriff (PDF)

NCCAM/NCI phase 1 study of mistletoe extract and Gemcitabine in patients with advanced solid tumors

Phytomedicine (Stuttgart), 2011-10, Vol.18 (13), p.S12-S12

2011

Volltextzugriff (PDF)

138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)

Annals of oncology, 2021-09, Vol.32, p.S419-S420

2021

Volltextzugriff (PDF)

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

Annals of oncology, 2024-07, Vol.35 (7), p.630-642

2024

Volltextzugriff (PDF)

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Annals of oncology, 2017-04, Vol.28 (4), p.761-768

2017

Volltextzugriff (PDF)

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

Annals of oncology, 2013-10, Vol.24 (10), p.2630-2635

2013

Volltextzugriff (PDF)

Tall tales from sly dwarves: novel functions of gibberellins in plant development

Trends in plant science, 2005-03, Vol.10 (3), p.123-129

2005

Volltextzugriff (PDF)

43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

Annals of oncology, 2021-05, Vol.32, p.S38-S39

2021

Volltextzugriff (PDF)

Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial

Annals of oncology, 2017-11, Vol.28 (11), p.2761-2767

2017

Volltextzugriff (PDF)

Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Annals of oncology, 2019-08, Vol.30 (8), p.1404-1404

2019

Volltextzugriff (PDF)

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Annals of oncology, 2021-05, Vol.32, p.S37-S38

2021

Volltextzugriff (PDF)

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Annals of oncology, 2018-07, Vol.29 (7), p.1607-1607

2018

Volltextzugriff (PDF)

Quantitative Evaluation of Fiber from Nonforage Sources Used to Replace Alfalfa Silage

Journal of dairy science, 1994-08, Vol.77 (8), p.2318-2331

1994

Volltextzugriff (PDF)

First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry

Annals of oncology, 2017-09, Vol.28, p.v90-v91

2017

Volltextzugriff (PDF)

Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry

Annals of oncology, 2017-09, Vol.28, p.v90-v90

2017

Volltextzugriff (PDF)

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer

ESMO open, 2022-06, Vol.7 (3), p.100475, Article 100475

2022

Volltextzugriff (PDF)

180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)

ESMO open, 2024-05, Vol.9, p.103202, Article 103202

2024

Volltextzugriff (PDF)

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

Breast cancer research and treatment, 2015-01, Vol.149 (1), p.163-169

2015

Volltextzugriff (PDF)

Gibberellin signal transduction presents …the SPY who O-GlcNAc'd me

Trends in Plant Science, 1999-11, Vol.4 (11), p.424-428

1999

Volltextzugriff (PDF)

Regulation of the early GA biosynthesis pathway in pea

Planta, 2005-12, Vol.222 (6), p.1010-1019

2005

Volltextzugriff (PDF)

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer

Annals of oncology, 2005-08, Vol.16 (8), p.1297-1304

2005

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Englisch
(101)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(69)
Physical Sciences
(33)
Life Sciences & Biomedicine
(31)
Physics
(28)
Astronomy & Astrophysics
(20)
Experiment
(20)
High Energy Physics - Experiment
(20)
Particle Physics
(20)
Physics, Nuclear
(20)
Physics, Particles & Fields
(20)
Female
(16)
Biological And Medical Sciences
(14)
Humans
(13)
Oncology
(13)
Exact Sciences And Technology
(11)
Gibberellins
(11)
Technology
(11)
Fundamental And Applied Biological Sciences. Psychology
(10)
Breast Neoplasms - Drug Therapy
(9)
Plant Sciences
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Physics Letters. B
(21)
Annals Of Oncology
(16)
Planta
(7)
Nuclear Fusion
(5)
Esmo Open
(2)
Exploratory Animal And Medical Research
(2)
Field Crops Research
(2)
Journal Of Animal Science
(2)
Journal Of Dairy Science
(2)
Osteoarthritis And Cartilage
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

Does CDKN2A loss predict palbociclib benefit?

HER2-Neu in Breast Cancer: History and Future Directions

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

NCCAM/NCI phase 1 study of mistletoe extract and Gemcitabine in patients with advanced solid tumors

138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC)

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

Tall tales from sly dwarves: novel functions of gibberellins in plant development

43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial

Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

Quantitative Evaluation of Fiber from Nonforage Sources Used to Replace Alfalfa Silage

First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry

Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer

180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

Gibberellin signal transduction presents …the SPY who O-GlcNAc'd me

Regulation of the early GA biosynthesis pathway in pea

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer

Suchergebnisse filtern